News Novartis sheds MorphoSys staff, sites after pelabresib delay Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.
News ICER identifies new crop of 'unsupported' drug price rises Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.
Oncology Can CAR-T first movers keep pace in a rapidly evolving marke... The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.
News Novartis bid to block generic Entresto in US suffers setback An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.
News Novartis pays $1bn upfront for Huntington's drug from PTC Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.
News Kisqali gets early breast cancer approval in Europe Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours
Spotlight on World Without Disease initiative: 2024 update In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.